Daraxonrasib (also known as RMC-6236), a targeted RAS(ON) pathway inhibitor, has continued to generate the most recent “KRAS target” headlines based on new clinical activity updates—especially in RAS-mutant pancreatic ductal adenocarcinoma (PDAC).[6][8]
Daraxonrasib is discussed as targeting KRAS by inhibiting RAS signaling in its “on” state, and recent reporting emphasizes its broader coverage across RAS/variant forms relevant to pancreatic cancer biology—not just a single KRAS mutation.[6]
If you tell me whether you mean (1) pancreatic cancer only or (2) all cancers with KRAS, I can narrow the “latest news” to the most relevant sub-trials and mutation classes.
KRAS mutations, which induce proliferative signaling driving many human cancers, are detectable in a small subset of osteosarcoma patients. The recently developed pan-KRAS inhibitor daraxonrasib, also known as RMC-6236, is capable of targeting a ...
pmc.ncbi.nlm.nih.govThe targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.
www.eurekalert.orgIn conclusion, daraxonrasib has superiority over selective KRAS mutant inhibitors specifically targeting KRAS^G12C^, KRAS^G12D^, or KRAS^G12V^. First, daraxonrasib has a broad-spectrum activity against both mutant and WT KRAS, HRAS, and NRAS isoforms.
pmc.ncbi.nlm.nih.govThe targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.
www.news-medical.netFDA has granted Breakthrough Therapy Designation to daraxonrasib, a RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) in patients with KRAS G12 mutations. - The designation represents a significant regulatory milestone for targeting KRAS mutations in pancreatic cancer, one of the most challenging malignancies to treat. - Daraxonrasib's multi-selective RAS(ON) inhibition mechanism offers a novel therapeutic approach for patients with...
trial.medpath.comDaraxonrasib earned FDA breakthrough therapy designation for previously treated metastatic PDAC harboring KRAS G12X mutations.
www.onclive.comTreatment with daraxonrasib at the phase 3 dose of 300 mg was well tolerated, had favorable dose intensity, and showed efficacy in RAS–mutated PDAC.
www.onclive.comA new drug targeting the KRAS mutation is transforming outcomes for pancreatic cancer patients, potentially opening doors for other cancers.
longevitytoday.com